Analysts predict that Agile Therapeutics, Inc. (NASDAQ:AGRX) will announce earnings per share of ($0.25) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Agile Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.24) and the lowest estimate coming in at ($0.27). Agile Therapeutics reported earnings per share of ($0.27) in the same quarter last year, which suggests a positive year over year growth rate of 7.4%. The company is scheduled to issue its next quarterly earnings results on Monday, November 6th.

According to Zacks, analysts expect that Agile Therapeutics will report full year earnings of ($1.02) per share for the current financial year, with EPS estimates ranging from ($1.06) to ($0.94). For the next fiscal year, analysts forecast that the business will report earnings of ($0.82) per share, with EPS estimates ranging from ($1.39) to ($0.09). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Agile Therapeutics.

Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings results on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.02. During the same quarter in the previous year, the firm earned ($0.29) EPS.

A number of research firms recently issued reports on AGRX. Noble Financial reissued a “buy” rating on shares of Agile Therapeutics in a report on Sunday, July 30th. Royal Bank Of Canada set a $8.00 price objective on shares of Agile Therapeutics and gave the stock a “buy” rating in a report on Sunday, July 16th. Janney Montgomery Scott reissued a “buy” rating and issued a $13.00 price objective (down previously from $15.00) on shares of Agile Therapeutics in a report on Thursday, August 24th. HC Wainwright began coverage on shares of Agile Therapeutics in a report on Wednesday, July 19th. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, ValuEngine downgraded shares of Agile Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Agile Therapeutics has an average rating of “Buy” and a consensus target price of $10.20.

Shares of Agile Therapeutics (NASDAQ AGRX) traded up 1.68% during mid-day trading on Wednesday, hitting $4.85. 304,024 shares of the company were exchanged. The company’s market capitalization is $139.71 million. The company has a 50 day moving average of $3.71 and a 200 day moving average of $3.63. Agile Therapeutics has a 52 week low of $1.82 and a 52 week high of $7.95.

In related news, Chairman Alfred Altomari bought 10,000 shares of the stock in a transaction dated Friday, August 25th. The shares were purchased at an average price of $3.34 per share, with a total value of $33,400.00. Following the completion of the acquisition, the chairman now owns 161,587 shares of the company’s stock, valued at $539,700.58. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 3.50% of the stock is owned by insiders.

Hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada lifted its holdings in shares of Agile Therapeutics by 608.0% in the second quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock worth $122,000 after buying an additional 27,907 shares in the last quarter. Janney Montgomery Scott LLC purchased a new position in shares of Agile Therapeutics in the second quarter worth $122,000. Susquehanna International Group LLP purchased a new position in shares of Agile Therapeutics in the second quarter worth $205,000. LMR Partners LLP purchased a new position in shares of Agile Therapeutics in the second quarter worth $211,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of Agile Therapeutics in the second quarter worth $309,000. 67.59% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Agile Therapeutics, Inc. (AGRX) Expected to Post Earnings of -$0.25 Per Share” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/10/04/agile-therapeutics-inc-agrx-expected-to-post-earnings-of-0-25-per-share-2.html.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.